BMJ Open (Sep 2022)

Munich atopy prediction study (MAPS): protocol for a prospective birth cohort addressing clinical and molecular risk factors for atopic dermatitis in early childhood

  • Sarah Preis,
  • Lea Schmidt,
  • Linda Tizek,
  • Maximilian Schielein,
  • Viktoria Lang,
  • Rachela Bleuel,
  • Anna Duswald,
  • Sebastian Sitaru,
  • Annette Blasini,
  • Christine Gasteiger,
  • Lennard Merdha,
  • Zsuzsanna Kurgyis,
  • Bettina Kuschel,
  • Evelyn Hauenstein,
  • Maximilian Sander,
  • Sebastian Niedermeier,
  • Desiree Argiriu,
  • Sabrina Engel,
  • Yuliya Skabytska,
  • Rafaela L Silva,
  • Miriam Hils,
  • Beatrix Evers,
  • Susanne Kaesler,
  • Hanna Hufnagel,
  • Martin Köberle,
  • Yacine Amar,
  • Alexander Zink,
  • Tilo Biedermann

DOI
https://doi.org/10.1136/bmjopen-2021-059256
Journal volume & issue
Vol. 12, no. 9

Abstract

Read online

Introduction The pathogenesis of atopic diseases is highly complex, and the exact mechanisms leading to atopic dermatitis (AD) onset in infants remain mostly enigmatic. In addition to an interdependent network of components of skin development in young age and skin barrier dysfunction underlying AD development that is only partially understood, a complex interplay between environmental factors and lifestyle habits with skin barrier and immune dysregulation is suspected to contribute to AD onset. This study aims to comprehensively evaluate individual microbiome and immune responses in the context of environmental determinants related the risk of developing AD in the first 4 years of a child’s life.Methods and analyses The ‘Munich Atopic Prediction Study’ is a comprehensive clinical and biological investigation of a prospective birth cohort from Munich, Germany. Information on pregnancy, child development, environmental factors, parental exposures to potential allergens and acute or chronic diseases of children and parents are collected by questionnaires together with a meticulous clinical examination by trained dermatologists focusing on allergies, skin health, and in particular signs of AD at 2 months after birth and then every 6 months. In addition, skin barrier functions are assessed through cutometry, corneometry and transepidermal water loss at every visit. These measurements are completed with allergy diagnostics and extensive microbiome analyses from stool and skin swabs as well as transcriptome analyses using skin microbiopsies.The aim is to assess the relevance of different known and yet unknown risk factors of AD onset and exacerbations in infants and to identify possible accessible and robust biomarkers.Ethics and dissemination The study is approved by the Ethical Committee of the Medical Faculty of the Technical University of Munich (reference 334/16S). All relevant study results will be presented at national and international conferences and in peer-reviewed journals.